Elranatamab
- Generic Name
- Elranatamab
- Brand Names
- Elrexfio
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 2408850-14-4
- Unique Ingredient Identifier
- L0HR9A577V
- Background
Elranatamab is a bispecific B-cell maturation antigen (BCMA)-directed CD3 T-cell engager. It is a humanized immunoglobulin 2-alanine kappa antibody derived from two monoclonal antibodies (mAbs), an anti-BCMA mAb and an anti-CD3 mAb, each of which contributes one heavy chain and one light chain to drug structure. The resulting 4-chain bispecific antibody is c...
- Indication
Elranatamab is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.
...
- Associated Conditions
- Refractory Multiple Myeloma, Relapsed Multiple Myeloma
- Associated Therapies
- -
Elranatamab in Relapsed/Refractory Multiple Myeloma
- First Posted Date
- 2024-12-02
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- University of California, San Diego
- Target Recruit Count
- 33
- Registration Number
- NCT06711705
Mezigdomide and Elranatamab for Relapsed And/or Refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2024-10-17
- Last Posted Date
- 2024-11-15
- Lead Sponsor
- YOUNGIL KOH
- Target Recruit Count
- 75
- Registration Number
- NCT06645678
- Locations
- 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of
A Study to Learn About the Effectiveness of the Medicine Called Elranatamab in People With Relapsed Refractory Multiple Myeloma as Compared With Standard of Care Therapies
- Conditions
- Interventions
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2024-10-04
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1
- Registration Number
- NCT06592222
- Locations
- 🇺🇸
Pfizer, New York, New York, United States
Korean Post Marketing Surveillance for ELREXFIO (Elranatamab).
- First Posted Date
- 2024-09-03
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 150
- Registration Number
- NCT06581848
- Locations
- 🇰🇷
Pfizer Korea, Seoul, Korea, Republic of
Elranatamab in Patients with Relapsed or Refractory AL Amyloidosis
- First Posted Date
- 2024-08-23
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- Brigham and Women's Hospital
- Target Recruit Count
- 49
- Registration Number
- NCT06569147
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
A Study to Compare the Effects of Elranatamab (PF 06863135) Versus Standard of Care (SOC) in Patients With Multiple Myeloma (MM) in Germany and US
- First Posted Date
- 2024-07-16
- Last Posted Date
- 2024-07-16
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 2
- Registration Number
- NCT06504524
- Locations
- 🇩🇪
Pfizer, Berlin, Germany
A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (MagnetisMM-30)
- First Posted Date
- 2024-01-22
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 87
- Registration Number
- NCT06215118
- Locations
- 🇨🇦
CIUSSS de l'Est-de-l'Île-de-Montréal, Montreal, Quebec, Canada
🇺🇸Emory University Hospital Midtown, Atlanta, Georgia, United States
🇺🇸Emory University Hospital, Atlanta, Georgia, United States
Pre-transplant Purging and Post-transplant MRD-guided Maintenance Therapy With Elranatamab in Patients With High-risk Multiple Myeloma
- First Posted Date
- 2024-01-17
- Last Posted Date
- 2024-11-28
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 40
- Registration Number
- NCT06207799
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
Use of Elranatamab in Patients With High-risk Smoldering Multiple Myeloma
- First Posted Date
- 2023-12-27
- Last Posted Date
- 2024-10-18
- Lead Sponsor
- Stichting European Myeloma Network
- Target Recruit Count
- 50
- Registration Number
- NCT06183489
- Locations
- 🇳🇱
Erasmus MC, Rotterdam, Netherlands
🇮🇹Ospedale Santo Spirito Ospedale -Azienda Sanitaria Locale Di Pescara, Roma, Italy
🇮🇹A.O.U. Policlinico S. Martino - Ematologia, Genova, Italy
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
- Conditions
- Interventions
- First Posted Date
- 2023-11-30
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 492
- Registration Number
- NCT06152575
- Locations
- 🇺🇸
Community Health Network, Inc., Indianapolis, Indiana, United States
🇺🇸Cayuga Cancer Center at Cayuga Park, Ithaca, New York, United States
🇺🇸Cayuga Medical Center, Ithaca, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.